• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

Poll: What Were the Most Important Biosimilar Findings Presented at ASCO?

Article

Diverse findings on biosimilar safety and savings were presented at the American Society for Clinical Oncology (ASCO) 2021 Annual Meeting.

Which of these biosimilar presentations at ASCO was most important?

For patients receiving myelosuppressive chemotherapy for breast and lung cancer, same-day pegfilgrastim to combat febrile neutropenia is safe and effective.
In real-world studies, the trastuzumab biosimilars Kanjinti and Zedora demonstrate comparable safety vs Herceptin for breast and gastrointestinal cancer.
The Oncology Care Model lowers use of supportive-care medications and boosts filgrastim biosimilar use.
Oncologists’ use of 3 biosimilars soared from 2019 to 2020.
Texas Oncology’s automatic biosimilar switching program led to single-month savings of $4 million (21%) among 460 health care practitioners.

Newsletter

Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.

Recent Videos
Travis Brewer, Texas Oncology
Tiago Biachi, MD, PhD
Lakesha Farmer, PharmD
© 2025 MJH Life Sciences

All rights reserved.